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The Janus kinase 2 (JAK2) mutant v617F and other JAK mutants 
are found in patients with myeloproliferative neoplasms 
and leukemias. Due to their involvement in neoplasia 
and inflammatory disorders, Janus kinases are promising 
targets for kinase inhibitor therapy. Several small-molecule 
compounds are evaluated in clinical trials for myelofibrosis, 
and ruxolitinib (iNCB018424, Jakafi®) was the first Janus kinase 
inhibitor to receive clinical approval. in this review we provide 
an overview of JAK2v617F signaling and its inhibition by small-
molecule kinase inhibitors. in addition, myeloproliferative 
neoplasms are discussed regarding the role of JAK2v617F and 
other mutant proteins of possible relevance. we further give 
an overview about treatment options with special emphasis 
on possible combination therapies.
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Introduction
Soon after their discovery1 the Janus kinases were found to be 
involved in cytokine signaling.2 The phenotypic analysis of 
knock-out mice for all four JAKs revealed that the lack of each 
JAK protein is linked to deficiencies in the signaling of spe-
cific cytokines using these JAKs in their receptor complexes3-8 
(reviewed in refs. 9 and 10). Janus kinase 2 is essential in the 
signaling of cytokines using homodimeric receptors (Epo, Tpo, 
prolactin, leptin, and growth hormone). It has been shown that 
JAK2 plays a crucial role in hematopoiesis as JAK2 knockout 
mice die at day 13 of gestation due to failure of the development 
of definite hematopoiesis.4,5 JAK2 also plays a central role in the 
signaling of cytokines employing the common β chain receptor 
(IL3, IL5, and GM-CSF), of certain members of the IL10 type 
cytokine family (IFNγ, IL19, IL20, and IL24), of the IL12 type 
family members (IL12 and IL23) and in TSLP signaling.11
Many detailed studies have shown how the four members of 
the Janus kinase family mediate cytokine-induced signal trans-
duction through cytokine receptors and regulate proliferation, 
differentiation, survival, and cell migration and thereby play a 
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The pseudokinase domain mutations (e.g., V617F) are thought 
to relieve the negative regulatory interaction between the pseudo-
kinase domain and the kinase domain36,38 and result in constitu-
tive activation of the kinase. Recently, the pseudokinase domain 
has been described to have residual kinase activity and to phos-
phorylate inhibitory amino acid residues within JAK2 (serine 
523 and tyrosine 570).39 This might imply that mutations in the 
pseudokinase domain could alternatively represent loss-of-func-
tion mutations regarding the pseudokinase domain’s remaining 
kinase activity. Still, the pseudokinase domain mutations are not 
fully understood, while the consequences of the mutations within 
the FERM and SH2 domains are not understood at all. This 
is due to the lack of detailed structural information concerning 
the full-length JAK proteins. Structural models of JAK240,41 have 
been used to explain the molecular details of processes involved 
in JAK2V617F activation.42-44 However, 3D reconstructions of 
isolated JAK1 from an electron microscopy imaging approach45 
have shown that the pseudokinase and kinase domain form a 
closely associated cluster, the conformation of which does not 
correspond to the molecular model described above. The isolated 
JAK1 showed great flexibility and could adopt different con-
formations from an “open” conformation (relatively linear with 
contacts between the adjacent domains in the polypeptide chain) 
to a “closed” conformation (in addition to contacts between adja-
cent domains, the FERM, SH2 domains are in contact with the 
kinase and pseudokinase domains). Although mutational studies 
have already suggested these contacts between the FERM and 
kinase domains,46-48 there is no certainty that the conformation 
of the JAKs bound to a cytokine receptor is entirely comparable 
to these conformational states. Unfortunately, the conformation 
of JAK1 bound to gp130 could not be resolved in this study. This 
might show that even when bound to a cytokine receptor the 
JAKs have great conformational flexibility.
JAK activation at the receptor. Janus kinases are tightly 
associated to the intracellular parts of cytokine receptors medi-
ated by their FERM and SH2 domains and are maintained in 
an inactive state, when no cytokine is bound to the receptor.35 
Binding of a cytokine to a cytokine receptor leads to confor-
mational changes in the receptor which are transmitted to the 
cytoplasmically associated JAKs, leading to their activation and 
phosphorylation (reviewed in refs. 11 and 35). Recently, a study 
using kinase-inactive and constitutively active mutants of JAK1 
and JAK3 in the context of IL-2 receptor signaling suggested that 
the conformational and phosphorylation events of JAK activation 
are independent of one another (Fig. 1), and that both events are 
necessary to induce full activation of the JAKs.37 However, the 
exact molecular details of JAK activation upon binding of a cyto-
kine to the receptor remains elusive, because of lacking structural 
information of the full-length protein bound to a receptor. The 
transformation potential of JAK2V617F is also dependent on 
binding to a cytokine receptor (EpoR, thrombopoietin receptor 
[TpoR], or G-CSF receptor)49 and it has been demonstrated that 
a functional FERM domain as well as an intact SH2 domain are 
required for the JAK2V617F-mediated transformation.50,51
JAK2V617F-mediated activation of diverse signaling path-
ways. The activated JAKs phosphorylate tyrosine residues in 
major role in hematopoiesis and the immune system. Due to this 
immunomodulatory role it is evident that Janus kinases are major 
regulators of inflammatory disorders (e.g., rheumatoid arthritis 
and psoriasis12) and cytokine-dependent cancers (e.g., multiple 
myeloma13) and, thus, have long been identified as druggable 
targets. Mutations in JAKs have first been described for JAK3 
and have been found to elicit severe combined immunodeficiency 
(SCID).14 Fusion of JAK2 with certain proteins (e.g., Tel, Bcr, 
or PCM1) resulting in constitutively active signaling molecules 
has been described in a variety of hematopoietic malignancies as 
CML, AML, or ALL.15-18
Additionally, a point mutation in JAK2—JAK2V617F—was 
discovered in the majority of Philadelphia chromosome-nega-
tive myeloproliferative neoplasm (MPN) patients in 2005.19-23 
JAK2V617F is found with high incidence in patients with poly-
cythemia vera (PV), essential thrombocythemia (ET), and pri-
mary myelofibrosis (PMF). In different murine models, it has 
been shown that the expression of JAK2V617F is sufficient to 
induce a MPN-like phenotype.24-29 JAK2V617F is also, albeit 
rarely, found in other hematologic malignancies like the hypereo-
sinophilic syndrome (HES), chronic or juvenile myelomonocytic 
leukemia (CMML or JMML), acute myeloid leukemia (AML), 
and refractory anemia with ringed sideroblasts (with thrombocy-
tosis) (RARS or RARS-T) (reviewed in ref. 11). The JAK2V617F 
mutation is an acquired somatic event of the hematopoietic com-
partment, where it has been identified in hematopoietic stem cells 
(CD34+CD38−CD90+lin−) and multi-potent progenitor cells22,30 
as well as in differentiated cells like granulocytes.20 It was also 
found in cells from the lymphoid lineage (e.g., natural killer cells) 
in a considerable amount of MPN patients31,32 suggesting that 
JAK2V617F occurs in multi-potent hematopoietic progenitor 
cells, although the phenotype of MPN is related to a selective 
proliferative advantage of the myeloid lineages. In the last years, 
many more genetic alterations affecting all members of the Janus 
kinase family have been discovered in leukemias and other hema-
topoietic neoplasia.11
JAK-STAT Signaling and the JAK2V617F Mutant
Structural organization of JAKs. The size of Janus kinases 
ranges from 120 to 140 kDa. All JAK family members share 
a similar sequence consisting of seven JAK homology (JH) 
domains,33 which only partially match the JAK domain struc-
ture. The JH1 and JH2 domains represent the adjacent kinase 
and pseudokinase domain, a feature only found in five kinases 
(in the four JAKs and in GCN2). The domains JH3 to JH7 cor-
respond to the SH2 and FERM domains33,34 and are involved in 
cytokine receptor binding. Structural aspects of receptor binding 
have been reviewed recently11,35,36 and will not be covered here. 
Since the discovery of JAK2V617F, a great number of mutations 
(~70) have been described throughout all the structural domains 
of the JAKs and many (~30) have been biochemically validated 
to lead to constitutively active proteins.37 Mutations in the kinase 
domain can have direct consequences on kinase domain confor-
mation and activation, but the molecular consequences of muta-
tions in other domains of the JAKs are not as easily understood. 
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upregulated by JAK2V617F-mediated signaling,50,57 have been 
described to inactivate Bad by phosphorylation, thereby activat-
ing the anti-apoptotic BclxL.57 Akt can also display its anti-apop-
totic role via phosphorylation of BH3-only proteins resulting in a 
recruitment of Bcl2 and BclxL to the mitochondrial membrane.64 
Furthermore Akt can inactivate Gsk3 by phosphorylation, thus 
impairing normal downstream Gsk3 functions such as inhibition 
of the cell cycle (e.g., by phosphorylation of cyclin/cyclin-depen-
dent kinase complexes or by inhibition of mitotic transcription 
factors) or promotion of apoptosis (e.g., by increasing BH3-only 
protein [Bax/Bak]-mediated apoptosis or by inhibition of Bcl2 
family member expression).64,67,68 Inhibition of FOXO by Akt is 
also known to lead to a downregulation of pro-apoptotic BH3-
only proteins. Interestingly, the activation of Gsk3 by DNA dam-
age stress was shown to synergize with JAK inhibitors in inducing 
apoptosis in cells expressing JAK2V617F.69
Additionally, it has also been described that JAK2V617F phos-
phorylates a histone arginine methyltransferase (PRMT5) and 
thus inhibits its activity resulting in altered chromatin modifica-
tions and gene expression.70 This contributes then to myelopro-
liferation and erythroid differentiation in JAK2V617F-positive 
cells. JAK2 has been described to phosphorylate histone H3 at 
tyrosine 41 resulting in the displacement of heterochromatin 
the cytoplasmic part of the receptor, thereby providing docking 
sites for SH2 domain-containing signaling molecules (Fig. 2). 
JAK2V617F leads to constitutive activation of downstream 
signaling through the JAK-STAT (STAT5 and STAT3), the 
MAPK, and the PI3K/Akt pathways,23,49,52,53 which lead to the 
expression of the mitotic serine/threonine-protein kinases Pim, 
anti-apoptotic genes (BclxL and Bcl2), and cell cycle regulatory 
proteins (cyclin D1 and Cdc25A).54-58 This results in a prolifera-
tive advantage of the affected cells.23 It has recently been shown 
that STAT5 is absolutely essential for the cellular transformation 
mediated by JAK2V617F,59-61 whereas activation of Akt might 
also play a role in the process of transformation.62 JAK2V617F 
has been implicated in promoting transition from G1 to S phase 
of the cell cycle which could be reverted by the inhibition of 
JAK2V617F with a small molecule JAK inhibitor.63 The inhi-
bition of JAK2V617F correlated with a decreased expression of 
cyclin D2 and an increased expression of the cyclin-dependent 
kinase (Cdk) inhibitor 1B (p27Kip1) (Fig. 2). p27 expression could 
also be blocked by Akt- or Erk1/2-mediated phosphorylation and 
subsequent degradation of FOXO transcription factors.64,65 JAK2 
has also been reported to phosphorylate p27Kip1, thereby impair-
ing its function and stability, which then leads to partial activa-
tion of Cdk and cell cycle progression.66 Pim kinases, which are 
Figure 1. Conformational and phosphorylation events leading to JAK activation. iL2 signaling is used as an example. For clarity only the signal trans-
ducing receptor chains (iL2rβ [β] and iL2rγ [γ]) are shown. The scheme on the left shows the inactive state of a receptor/JAK complex. The binding of 
the cytokine (1a) impinges conformational changes in the receptor complex. JAKs are sensitive to these changes since they bind to the membrane-
proximal region of cytokine receptors. This results in a conformational, phosphorylation-independent activation of the two JAKs (1b). Activation of 
downstream signaling is already promoted at this stage (2), although at a non-maximal level. The now activated JAKs phosphorylate each other “in 
trans” (3a and 3b). This leads to a full-fledged activation of the JAKs and maximal downstream signaling (4) (here: STAT5 phosphorylation). The differ-
ent steps of the activation process are derived from a study using kinase-inactive, constitutively active and analog-sensitive mutants of JAK1 and JAK3 
in the context of iL2 signaling.37
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in this process remains controversial,72 and it cannot be excluded 
that a kinase downstream of JAK2V617F may be involved in 
protein (HP) 1α71 leading to expression of leukemogenic onco-
genes like LMO2. However, the direct implication of JAK2V617F 
Figure 2. For figure legend, see page 5.
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E3 ubiquitin ligase activity. Among the two types of ubiquitin 
ligases, SOCS and CBL proteins are both part of the RING 
finger E3 family, but they belong to different subgroups. While 
CBL proteins are single subunit E3s (having the RING finger and 
the substrate recruiting subunit on the same polypeptide chain), 
the SOCS proteins are part of the multi-subunit E3s (including 
a small RING finger protein, a member of the Cullin family, 
and multiple other subunits among which there is the substrate 
recruiting domain).96
The suppressor of cytokine signaling (SOCS) protein97 family 
(all having a central SH2 domain and a C-terminal SOCS box) 
comprises eight family members (SOCS1–7 and CIS) that can 
suppress JAK-STAT signaling by inhibiting JAK kinase activity, 
by competing with STAT factors for docking sites on the cyto-
kine receptor and/or by facilitating the proteasomal degrada-
tion of signaling proteins. Constitutively active JAK2 mutants 
are susceptible to negative regulation by SOCS proteins, show 
decreased stability, increased ubiquitination, and are degraded via 
the proteasome.52 Thus, mechanisms interfering with this nega-
tive regulation could considerably contribute to the development 
and progression of MPNs by increasing the levels of constitu-
tively active JAK2 mutants, although this is still under debate.98 
Mechanisms that were reported to interfere with SOCS func-
tion are methylation,99-101 mutations,102 and deletions103 of SOCS 
genes. Importantly, epigenetic silencing of SOCS3 and SOCS1 
was recently reported in about 40% of patients with Philadelphia 
chromosome-negative chronic myeloid disorders.104,105 The Casitas 
B-cell lymphoma (CBL) family consists of 3 mammalian mem-
bers, CBL, CBL-b, and CBL-c. All CBL proteins have a conserved 
N-terminal tyrosine kinase binding domain (TKB) (itself com-
prised of a 4-helix bundle [4H], an EF-hand [EF] and an atypi-
cal SH2 domain) connected by an α-helical linker to a RING 
finger (RF) domain. C-terminally to the RF, CBL proteins con-
tain proline-rich sequences, tyrosine residues and an ubiquitin-
associated domain (UBA). CBL proteins can function as ubiquitin 
ligases but are also adaptor proteins which can mediate signal 
transduction events by offering binding sites for SH3 and SH2 
domain-containing proteins.106 CBL proteins are known to medi-
ate ubiquitination and degradation of kinases and were described 
to interact with many receptor tyrosine kinases, cytokine recep-
tors, and cytoplasmic kinases (including the JAKs) and oncogenic 
mutants of CBL have been reported to uncouple kinases from deg-
radation.107-109 CBL mutations are also found in myeloproliferative 
neoplasms110-113 and have been associated with a poor prognosis.
Myeloproliferative Neoplasms and JAK2 Mutations
Myeloproliferative neoplasms. Myeloproliferative neoplasms are 
characterized by a dysregulated enhanced proliferation of one or 
promoting this nuclear function. An active JAK homolog, HOP, 
in Drosophila has also been implicated in changes of chromatin 
condensation and STAT-independent gene transcription.73
Negative Regulatory Mechanisms of JAK Activity
To prevent a permanent and/or excessive activation of JAK-STAT 
signaling a number of negative regulatory mechanisms that mod-
ulate the pathway at different levels have been reported.
Phosphatases and PIAS proteins. Negative regulatory mech-
anisms include the dephosphorylation of cytokine receptors, 
JAKs or STATs by protein tyrosine phosphatases (PTP)74 or the 
prevention of STAT factors to bind DNA by protein inhibitors of 
activated STAT (PIAS).75 No specific regulations of JAK-STAT 
phosphatases or PIAS family members have been reported for 
JAK2V617F to our knowledge.
SH2B protein family members. LNK (SH2B3), an adaptor 
protein comprising a dimerization domain, proline-rich regions, 
a PH domain, and an SH2 domain, negatively regulates acti-
vated JAK2 by directly binding to the phosphorylated tyrosine 
residue 813 via its SH2 domain.76,77 LNK has been reported to 
negatively regulate TpoR and EpoR signaling.78,79 LNK muta-
tions have been detected in JAK2V617F-positive and -negative 
myeloproliferative neoplasms80-83 and LNK mRNA in MPN 
patients was reported to positively correlate with JAK2V617F 
allele burden.84 Interestingly, other family members, SH2B1 
(SH2Bβ) and SH2B2 (APS), have been described to associate 
with Janus kinases and to positively85-87 or negatively88-90 regulate 
their kinase activity. Concerning EpoR signaling, however, all 
three family members have been reported to act as negative regu-
lators (SH2B190). Moreover, SH2B2 was reported to cooperate 
with CBL (see below) in doing so.88
Regulation of JAK and receptor protein expression (inter-
nalization, SOCS, and CBL). On the cellular52 and the organism 
level as well as in patients (see sections below) it is well established 
that the levels of mutant JAK2V617F protein influence the signal-
ing intensity and its pathological consequences. This underscores 
the importance of understanding the regulation of the cytokine 
receptor/JAK complexes at the protein level.
Cytokine signaling can be regulated on the level of plasma 
membrane localization of receptor/JAK complexes. Cytokine 
receptor/complexes can be internalized and processed either for 
recycling back to the plasma membrane or be targeted for deg-
radation of their components via the lysosome or proteasome91-93 
(reviewed in ref. 94). JAK2V617F has been described to lead to 
the internalization, ubiquitination, and degradation of TpoR.95
Downregulation by ubiquitination in the JAK-STAT pathway 
has been described to be mediated by two families of proteins, 
SOCS proteins and CBL proteins. Both types of proteins possess 
Figure 2 (See previous page). Schematic representation of pathways related to signaling of JAK2v617F and regulation of its expression levels. A num-
ber of possible pharmacological approaches have been described that target proteins in the scheme (e.g., mTOr, MeK, HSP90, Aurora A/B, …). Other 
kinases involved in these pathways (e.g., Pi3K, Akt, Pim, erk1/2, …) might also be promising targets for combination treatments. in addition to Aurora 
kinases, further kinases influencing cell cycle progression also represent interesting targets (cyclin-dependent kinases [Cdk] and polo-like kinases 
[Plk]). inhibition of the Bcl-2 family members might counteract anti-apoptosis. interference with JAK expression levels has been shown to suppress 
JAK-STAT signaling either by inhibiting chaperone functions (HSP90) or by using deubiquitinase inhibitors.216 Future approaches could also involve the 
targeting of adaptor proteins such as GAB1/2 which orchestrate the activation of the different signaling pathways in the signalosome at the receptor.
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The course of PV can be divided into three 
phases:124 (1) the pre-polycythemic phase char-
acterized by a borderline or mild erythrocytosis 
often in combination with significant thrombo-
cytosis (sometimes associated with thrombotic 
events), (2) the apparent polycythemic phase, 
and (3) the post-polycythemic phase defined 
by cytopenia (including anemia), bone mar-
row fibrosis, and extramedullary hematopoi-
esis (post-polycythemia myelofibrosis). Almost 
all patients are diagnosed when they are in the 
polycythemic phase and the first symptoms 
appear. These include e.g., headache, dizziness, 
paresthesia, aquagenic pruritus, and erythromelalgia mainly due 
to thrombotic events in the microvasculature. However, a throm-
bosis of major blood vessels (e.g., splanchnic vein thrombosis) 
can occur as well. Additionally, many patients suffer from sple-
nomegaly and/or hepatomegaly. Upon appropriate treatment the 
survival time of PV is very much prolonged, but life expectancy 
of PV patients is nevertheless reduced when compared with that 
of the general population.125
The probability of PV patients to develop a post-polycythemic 
myelofibrosis is ~15% at 10 y and ~35% at 15 y after the ini-
tial diagnosis.126 A major risk factor to progress to myelofibro-
sis seems to be the JAK2V617F allele load since the incidence is 
much higher in patients with a high JAK2V617F allele burden 
compared with those with a low allele load.126,127 On the other 
hand, the incidence of progression to myelodysplastic syndromes 
(MDS) or acute myeloid leukemia (AML) is very low, but is 
increased with higher age at diagnosis or due to treatment with 
certain cytotoxic agents (e.g., busulfan or pipobroman128).
Essential thrombocythemia. ET has an annual incidence of 
0.5–2.5 per 100 000 people.129 It can occur at any age (including 
children), but the disease is mostly diagnosed in patients who 
are in their sixties or around 30 y old.130 Approximately half of 
the ET patients carry the JAK2V617F mutation; these patients 
mainly bear cells that are heterozygous for the mutation.120 About 
5% of the ET patients are positive for a mutation in exon 10 
of the Tpo receptor and additional 5% bear a mutation in the 
adaptor protein LNK. The remaining ET patients (~1/3) do not 
display any known mutation affecting the JAK-STAT signaling 
pathway (see Fig. 3).
Essential thrombocythemia is mainly characterized by an 
enhanced proliferation of the megakaryocytic lineage leading 
to sustained thrombocytosis (with a platelet count ranging from 
more than 450 to more than 2000 × 109/l). The platelets are not 
equal in size ranging from small to giant and display abnormal 
functions (e.g., spontaneous aggregation and activation) result-
ing in an increased risk of thrombosis and/or bleeding.131 The 
bone marrow of ET patients is typically normal or slightly hyper-
cellular apart from the megakaryocytic lineage. The number of 
megakaryocytes is elevated and megakaryocytes in ET patients 
have extremely lobulated nuclei and their size is increased varying 
from large to giant.
In general, ET is a rather indolent disorder with long symp-
tom-free periods and only occasional events of thrombosis or 
more of the myeloid lineages (i.e., the erythroid, granulocytic, 
megakaryocytic, and monocytic lineages), which is considered 
to result from genetic abnormalities at the level of hematopoietic 
stem/progenitor cells. Myeloproliferative neoplasms comprise 
chronic myeloid leukemia (Bcr-Abl-positive) (CML), polycythe-
mia vera (PV), essential thrombocythemia (ET), primary myelo-
fibrosis (PMF), chronic neutrophilic leukemia (CNL), chronic 
eosinophilic leukemia (CEL-NOS), mast cell disease, and 
unclassified myeloproliferative neoplasms (MPN-U). CML, PV, 
ET, and PMF were known since long to be clonal stem cell disor-
ders.114-117 Patients suffering from MPN usually show an increased 
amount of functional and terminally differentiated myeloid cells 
(i.e., erythrocytes, granulocytes, monocytes, and/or platelets) 
in their peripheral blood. However, the diseases can progress to 
ineffective hematopoiesis and failure of the bone marrow due to 
myelofibrosis and/or transformation to acute leukemia.
In addition to CML (for which the fusion protein kinase Bcr-
Abl was already identified as the disease-causing mutation118), 
three other MPNs (PV, ET, and PMF) were shown to harbor a 
mutated kinase—JAK2V617F,19,20,22,23,119 which can result from 
a heterozygous or homozygous mutation. Cells homozygous for 
JAK2V617F can be found in most of the PV patients but only 
rarely in ET patients.120 The homozygous mutation was demon-
strated to result from a duplication of the mutant allele by mitotic 
recombination.20-23
Polycythemia vera. Polycythemia vera (PV) is the only 
acquired primary polycythemia. It has an incidence of 1–3 per 
100 000 people per year and is most frequently diagnosed in peo-
ple aged between 60 and 70 y. The vast majority of PV patients is 
positive for the JAK2V617F mutation and most of them bear cells 
which are homozygous for the mutation.120 PV patients, who do 
not carry the JAK2V617F mutant, mostly display other activat-
ing mutations in exon 12 of JAK2 (see Fig. 3).121
Polycythemia vera is characterized by the dysregulated pro-
liferation of the erythroid, granulocytic, and/or megakaryocytic 
lineages. This leads to the hypercellularity of the bone marrow 
(i.e., panmyelosis) and an increase of the red cell mass in the 
peripheral blood as well as leukocytosis and thrombocytosis. 
However, patients with mutations in JAK2 exon 12 mainly dem-
onstrate an isolated erythrocytosis without associated increase of 
platelet number or white blood count.122,123 In contrast to PMF 
and ET, the megakaryocytes in PV show mainly a normal phe-
notype and size.
Figure 3. Proportion of patients with Pv, eT, or PMF carrying different genetic abnormali-
ties related to JAK-STAT signaling.
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However, the survival times can be much longer if the disease has 
been diagnosed in the prefibrotic stage.132,139 The main causes of 
death for PMF patients include the progression to acute leukemia 
(observed in 20% of the patients at 10 y of diagnosis), infec-
tion, and bleeding secondary to bone marrow failure, and portal 
hypertension or hepatic failure caused by hepatic vein thrombosis 
or extramedullary hematopoiesis.125
JAK2 mutations and other mechanisms contributing to PV, 
ET, and PMF. The discovery of an activating mutation down-
stream of cytokine receptors playing an essential role in myeloid 
hematopoiesis was a major breakthrough in understanding the 
development of the Philadelphia chromosome-negative MPNs. 
However, this raised the question of how a single mutation can 
lead to the development of three distinct diseases (PV, ET, and 
PMF). Subsequently, it was demonstrated in a murine bone mar-
row transplantation model introducing JAK2V617F-positive 
cells that the MPN phenotype was influenced by the genetic 
background of the respective mouse strain.140 Furthermore, the 
amount of JAK2V617F seems to play a role in the pathogenesis 
as well, given that cells that are homozygous for JAK2V617F are 
more often found in PV patients than in ET patients.120 This 
could be recapitulated in a JAK2V617F transgenic mouse model, 
which allowed the expression of varying ratios of JAK2 wild-type 
to JAK2V617F.25 Low expression of JAK2V617F resulted in a 
MPN phenotype resembling human ET, while higher expression 
of JAK2V617F led to a PV-like phenotype.
Since 2005, many more mutations affecting proteins impor-
tant in JAK-STAT signaling have been identified in JAK2V617F-
negative MPN patients (for a review see ref. 11). Scott and 
colleagues discovered several additional mutations in exon 12 
of JAK2 including K539L by sequencing JAK2 in JAK2V617F-
negative PV patients. Several more point mutations, deletions, 
and insertions affecting JAK2 exon 12 have been identified in 
PV patients since then.11,122 Somatic gain of function mutations 
often affecting the amino acid residues W515 and S505 have 
been found in the Tpo receptor gene (MPL) of patients with ET 
and PMF.141-145 Both JAK2 exon 12 (K539L) and Tpo receptor 
(W515K/L) mutants have been shown to lead to the transforma-
tion of BA/F3 cells and induce a MPN-like phenotype in murine 
bone marrow transplantation models.122,142 Furthermore, muta-
tions in adaptor proteins involved in the negative regulation of 
cytokine signaling, i.e., LNK and CBL, have been described in 
ET and PMF patients.80,112
A great variety of new data could contribute to understand 
the development of the three diseases with differing phenotypes. 
The high proportion of patients with ET and PMF not display-
ing any known mutation affecting JAK-STAT signaling shows 
that for these two diseases at least other players can be sufficient 
to induce the disease state. Indeed, further recurrent somatic 
mutants of different proteins (e.g., ASXL1, EZH2, IKZF1, 
IDH1/2, RUNX1, and TET2) have been found with variable 
frequency in PV, ET, and PMF.111,146 Some of the affected pro-
teins are implicated in the epigenetic regulation (e.g., ASXL1 and 
TET2), whereas IKZF1 and RUNX1 are transcription factors. 
The different mutations are not specific for any of the MPN sub-
types and can occur concomitantly with JAK2V617F or the other 
bleeding. Up to 50% of the patients are asymptomatic at diagno-
sis; the disease is then mostly detected by a routine examination. 
The other patients demonstrate symptoms related to thrombotic 
events in the microvasculature. However, the thrombosis of 
major blood vessels (leading to, e.g., seizures, stroke, myocardial 
infarct, and deep-vein thrombosis) can occur as well. The life 
expectancy of the majority of ET patients is near normal132 and 
only a minority of patients either progress to post-ET myelofibro-
sis or to AML.133
Primary myelofibrosis. Myelofibrosis is defined as an increase 
in quantity and density of extracellular matrix proteins, which 
normally provide a scaffold for the hematopoietic (stem and 
progenitor) cells in the bone marrow. Myelofibrosis can occur 
secondary to, e.g., infections and inflammatory or neoplastic 
disorders.
Primary myelofibrosis (PMF) occurs with an incidence of 
0.5–1.5 per 100 000 people per year. The median age at diagno-
sis is usually > 70 y.134 Importantly, the clinical characteristics 
of post-polycythemic or post-ET myelofibrosis are the same as 
for PMF in the fibrotic phase and can only be distinguished 
when the initial disease was well diagnosed. Approximately 
half of the patients with PMF carry the JAK2V617F mutant, 
whereas approximately 10% are positive for a mutation in exon 
10 of the Tpo receptor. Additionally, mutations in the adaptor 
proteins LNK or CBL can be found in PMF patients as well 
(each ~5%). The remaining PMF patients (~25%) do not dis-
play any known mutation affecting the JAK-STAT signaling 
pathway (see Fig. 3).
Primary myelofibrosis is characterized by enhanced prolif-
eration mainly of the megakaryocytic lineage and the alteration 
of the bone marrow structure including progressive myelofibro-
sis and hyperactive angiogenesis, which is often accompanied 
by extramedullary hematopoiesis. The disease course can be 
divided in two phases:124 The prefibrotic or early phase is char-
acterized by a hypercellular bone marrow (due to an increase 
of the megakaryocytic and the granulocytic lineages; eryth-
ropoiesis is often decreased) with no or slight reticulin fibro-
sis and an increased platelet count in the peripheral blood. 
The fibrotic phase displays a hypocellular bone marrow with 
marked reticulin and/or collagen fibrosis and also osteosclero-
sis. Megakaryocytes and platelets for instance produce PDGF, 
TGFβ, or OSM,135,136 which stimulate fibroblast proliferation 
and activity. The peripheral blood of PMF patients in the 
fibrotic phase demonstrates decreased erythrocyte levels up to 
anemia, low levels of large abnormal platelets, and also leukope-
nia. Moreover, the plasma levels of inflammatory cytokines (e.g., 
IL1β, IL6, IL8, IFNγ, and TNFα) are highly increased.137,138 In 
the advanced stages, bone marrow failure results in relocation 
of the hematopoiesis to other organs. Most common sites of 
extramedullary hematopoiesis are the spleen and the liver, but 
any other organ (e.g., kidney, lung, or the gastrointestinal tract) 
can be affected. Bone marrow failure also leads to high levels of 
CD34+ cells in the peripheral blood, which normally reside in 
the bone marrow.
The median overall survival of PMF patients who have been 
diagnosed in the fibrotic phase is approximately five years. 
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Janus Kinase Inhibitors in the Treatment of MPN
Classic treatment of MPNs. For PV and ET the treatment 
rationale is mainly the prevention of thrombotic complications 
which is the major reason for morbidity and mortality in these 
patients.174 Low-risk patients with PV are normally treated with 
phlebotomy and low-dose aspirin. High-risk PV patients addi-
tionally receive hydroxyurea or pegylated IFN-α as first-line 
treatment. ET patients at low thrombotic risk are either moni-
tored without therapeutic intervention or they receive low-dose 
aspirin as well. High-risk patients with ET are usually treated 
with hydroxyurea, pegylated IFN-α, or anagrelide.
There are several treatment approaches for patients with 
myelofibrosis that are primarily aimed at relieving the diverse 
disease symptoms and improve the patient’s quality of life. The 
only curative treatment of myelofibrosis is allogeneic hematopoi-
etic stem cell transplantation (HSCT). However, the mortality 
and morbidity of this procedure is still very high and it is ques-
tionable if it leads to substantial increase in overall survival for 
eligible patients.174 The main issues that are targeted by conven-
tional treatment strategies are anemia and splenomegaly/extra-
medullary hematopoiesis. Blood transfusion or treatment with 
corticosteroids, androgens or erythropoiesis-stimulating agents is 
used to treat the anemia. Anemia as well as splenomegaly can 
be treated with immunomodulatory agents like thalidomide or 
lenalidomide. Furthermore, cytoreductive drugs as hydroxyurea 
or pegylated IFNα or chemotherapeutic agents (e.g., cladribine 
or decitabine) are used to reduce the spleen size. Alternative treat-
ment options for splenomegaly/extramedullary hematopoiesis 
are radiation therapy or splenectomy, either of which is rare and 
only performed if no other treatment option is feasible. However, 
there is no evidence that any conventional treatment approach 
improves the constitutional symptoms.175 In addition, none of 
the conventional treatment strategies except allogeneic stem cell 
transplantation shows durable effects/benefits and they also dem-
onstrate significant toxicities.176-179
Treatment of MPN with JAK inhibitors. The discovery 
of the JAK2V617F mutant defined JAK2 as “druggable” tar-
get for Philadelphia chromosome-negative MPNs. Although 
JAK2V617F is not found in all patients with ET and PMF, an 
aberrant activation of the JAK-STAT signaling pathway plays 
a central role in the pathogenesis of most PV, ET, and PMF 
patients.162 The JAK-STAT pathway not only drives myelopro-
liferation but also mediates the activity of inflammatory cyto-
kines, whose levels are commonly increased in myelofibrosis 
patients.137,138 Since 2005, many inhibitors of JAK(2) have been 
developed; several of those are currently evaluated in clinical tri-
als (see Table 1).
INCB018424 (ruxolitinib, Jakafi®). To date, only ruxolitinib 
(INCB018424) received approval by the FDA (in November 
2011) and the European Commission (in August 2012) for the 
treatment of intermediate- and high-risk myelofibrosis (primary 
and post-PV/ET). Ruxolitinib is a JAK1 and JAK2 inhibitor.180 
The basis of its approval were two phase III clinical studies for 
myelofibrosis (COMFORT I and II) which provided evidence 
that application of ruxolitinib leads to the reduction of spleen size 
mutations. However, these mutations and/or their accumulation 
might partially explain the clinical differences among PV, ET, 
and PMF.147 Furthermore, some of the mutations are associated 
to disease progression and are more frequently found in post-
MPN acute leukemia (e.g., mutants of IDH1/2, IKFZ1, and also 
LNK146).
Additional mechanisms like epigenetic silencing, post-tran-
scriptional regulation or post-translational modifications could 
account for the development of different phenotypes. For instance, 
it has been reported that the SOCS1, SOCS2, and SOCS3 genes 
are hypermethylated in MPN.104,105,148-150 Furthermore, the com-
parison of microRNA expression in MPN patients and healthy 
controls identified among others miRNA-150 to be differentially 
expressed.151-153 Interestingly, miRNA-150 has been reported to 
regulate the lineage fate in megakaryocyte-erythrocyte progeni-
tor cells.154 Furthermore, Pardanani and colleagues found several 
germline single nucleotide polymorphisms (SNPs) in the region of 
the JAK2 gene that are different in PV and ET patients and could 
contribute to the differences in MPN phenotype.155 Subsequently, 
several groups reported that a common haplotype (referred to 
as “46/1”) in the JAK2 locus is associated with the acquisition 
of JAK2V617F as well as the development of MPN.156-158 They 
demonstrated that patients who were heterozygous for this hap-
lotype were significantly more likely to acquire JAK2V617F. The 
same haplotype also predisposes to mutations in JAK2 exon 12 
as well as in the Tpo receptor.159,160 However, the mechanism by 
which a germline SNP in the 46/1 haplotype increases the risk to 
develop MPN or acquire JAK2V617F or other mutations is not 
known. In general, the 46/1 haplotype seems to be a major germ-
line factor involved in MPN development and to date no other 
common SNP associated with MPN has been reported.147 The 
newly discovered genetic abnormalities also played a central role 
in the revision of the WHO classification for MPN in 2008161 as 
they can be used as diagnostic parameters. The new classification 
includes CML, the “classic” Philadelphia chromosome-negative 
MPN (PV, ET, and PMF) and several other rare diseases that 
demonstrate many features of MPN.
Inflammation and an aberrant activation of the JAK-STAT 
signaling pathway are also hallmarks of MPN162-165 irrespective of 
mutations influencing the JAK-STAT pathway. The JAK-STAT 
pathway not only drives myeloproliferation but also mediates the 
activity of inflammatory cytokines, whose levels are commonly 
increased in myelofibrosis patients.137,138 Since an initiating event 
in MPN is not known, inflammation has also been discussed 
to be an incipient event. It has been reviewed recently166 that 
inflammation can induce epigenetic changes and genomic muta-
tions. High levels of inflammatory cytokines and chemokines 
are found in the plasma of MPN patients and in supernatants 
of cells expressing JAK2V617F136-138,167-170 and a number of cyto-
kines, e.g., IL6, IL11, TNFα, and HGF have been reported to 
promote survival of cells carrying JAK2V617F.171-173 Cytokines 
are involved in the development of fibrosis, e.g., megakaryocytes 
and platelets produce PDGF, TGFβ, or OSM,135,136 which stimu-
late fibroblast proliferation and activity. On the other hand, the 
stroma also secretes cytokines, which regulate the behavior of 
JAK2V617F mutated cells.171-173
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since almost all PV patients either bear the JAK2V617F mutant 
or a mutation in exon 12 of JAK2. Thus, one might speculate 
that in the treatment of PV a JAK2-specific inhibitor (e.g., 
TG101348) might be more efficient; however, this remains to 
be shown. Ruxolitinib has been assessed in a phase II clinical 
trial in PV and ET patients intolerant or resistant to treatment 
with hydroxyurea.187 Application of ruxolitinib led to a decrease 
of hematocrit levels, platelet count, and JAK2V617F allele 
burden.188 The most common side effect was anemia for both 
patient cohorts, which was clinically well manageable. Two 
clinical studies on PV patients (http://www.clinicaltrials.gov/, 
NCT01243944 [RESPONSE] and NCT01632904 [RELIEF]) 
are currently being conducted.
TG101348 (SAR302503). TG101348, an inhibitor described 
to be specific for JAK2, is also evaluated in a phase II clinical 
trial in patients with PV and ET (http://www.clinicaltrials.gov/, 
NCT01420783). When tested in a phase I/II clinical trial in 
myelofibrosis patients, it led to the normalization of leukocytosis 
and thrombocytosis, while a decrease in inflammatory cytokine 
levels could not be observed for this compound.189 This suggests 
that TG101348 acts rather anti-proliferative than anti-inflamma-
tory. So it will be very interesting, how this inhibitor with a stron-
ger preference for JAK2 in in vitro kinase assays will perform in 
myelofibrosis, PV, and ET patients in comparison to ruxolitinib.
Other JAK inhibitors. Many potent JAK inhibitors (showing 
nanomolar activities in intact cell assays) have been developed in 
the last years and several are evaluated in clinical trials.177,190-193 
Table 1 shows promising JAK(2) inhibitors in clinical trials for 
MPN. More comparative studies of these inhibitors are needed 
to show possible differences of potency and to uncover poten-
tial additional activities of these compounds (see ref. 194). For 
instance CEP701, a JAK2 inhibitor, was recently shown to also 
and an improvement of symptoms.181,182 In addition, ruxolitinib 
decreases leukocytosis and thrombocytosis as well as inflamma-
tory cytokine levels and thereby enhances the patients’ quality 
of life. Recently, long-term results from the before mentioned 
studies have shown that ruxolitinib-treated patients have a sur-
vival advantage over the control groups (placebo in COMFORT 
I, best available therapy [BAT] in COMFORT II) and that the 
JAK2V617F allele burden was reduced (> 20% in 13% of the 
patients).181,183-186 Interestingly, also the requirement of blood 
transfusions (due to the side effects of anemia and thrombocyto-
penia) observed in the early phases for patients receiving ruxoli-
tinib decreased to rates similar to the control groups.
It will be interesting to determine to what extent the relief of 
symptoms in myelofibrosis patients by ruxolitinib is in fact due 
to the inhibition of inflammatory cytokine action (via its role as 
JAK1 and JAK2 inhibitor). This will probably only be recog-
nized when data from studies with more JAK2-specific inhibi-
tors advance to the same stage in clinical studies. As mentioned 
before, inflammatory cytokines are a hallmark of myelofibrosis 
(even in those cases without apparent mutations affecting the 
JAK-STAT pathway).
Also for the treatment of PV it will be interesting to fol-
low the performance of specific JAK2 vs. multi-JAK inhibitors 
since PV patients do not generally demonstrate elevated serum 
levels of inflammatory cytokines. In fact, the phenotype of PV 
is mainly characterized by myeloproliferation resulting in the 
increase of red blood cell count often accompanied by leuko-
cytosis and/or thrombocytosis. However some studies have 
shown that inflammatory cytokines are also detectable in PV 
and contribute to the growth of clonal erythroblast indepen-
dently of JAK2V617F.169,173 Additionally, the underlying mecha-
nism of PV is more closely connected to hyperactivated JAK2, 
Table 1. JAK inhibitors in clinical trials for myelofibrosis
Compound Targets Clinical trial Responses observed so far
AZD1418 JAK1/2217 i/ii No information available
BMS911543 JAK2218 i/ii No information available
CeP701 JAK2/3219 ii Splenomegaly ↓220
CYT387 JAK1/2, Tyk2168 ii
Splenomegaly ↓
improvement of constitutional symptoms
improvement of anemia221
LY2784544 JAK2222 ii
Splenomegaly ↓
improvement of constitutional symptoms
(improvement of bone marrow fibrosis)223
NS-018 JAK2224 i/ii No information available
SB1518
(Pacritinib)
JAK2, Tyk2225 i/ii
Splenomegaly ↓
improvement of constitutional symptoms226
TG101348 (SAr302503) JAK2227 iii
Splenomegaly ↓
improvement of constitutional symptoms
Normalization of leukocytosis and thrombocytosis
(JAK2v617f allele burden ↓)189
XL019 JAK2228 i/terminated Neuronal toxicity229
Status: October 2012, adapted from references 177, 190, 191, and 193.
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Additionally, compounds modifying the epigenome have 
been tested for their potential therapeutic activity in MPN. 
However, it is not clear if there is a therapeutic indication for 
DNA demethylation in MPN since the reports on alterations 
in DNA methylation patterns are controversial. Demethylating 
agents as azacitidine and decitabine are tested as single drug or 
in combination with JAK2 inhibitors in MPN patients.177 Barrio 
and colleagues found a homogeneous and very similar methyla-
tion pattern in MPN compared with healthy control popula-
tions.201 On the other hand, it was described that PV and ET 
are characterized by an aberrant hypermethylation while PMF 
is characterized by both aberrant hyper and hypomethylation.202 
Histone deacetylases (HDACs) are also known to epigenetically 
regulate gene expression by removing acetyl groups from lysine 
residues on histone proteins and also non-histone proteins like 
transcription factors.203,204 It has been shown that both the level 
and activity of HDACs are elevated in primary myelofibrosis 
patients.205 Therefore the potent pan-HDAC inhibitor panobi-
nostat (LBH589) has been evaluated in vitro in JAK2V617F-
positive cells.206 The treatment with panobinostat decreased 
JAK2V617F expression levels and its downstream signaling prob-
ably by mediating hyperacetylation of heat shock protein (HSP) 
90 and thereby disrupting the association between JAK2 and the 
chaperone, leading to its proteasomal degradation. Myelofibrosis 
patients treated with panobinostat as a single agent experienced 
an improvement of constitutional symptoms and a reduction of 
spleen size.205,207 Moreover, when applying a JAK2 inhibitor and 
panobinostat in combination, the proliferation of JAK2V617F-
positive cells was synergistically suppressed206 and demonstrated 
enhanced efficacy in comparison to each single agent in murine 
MPN models.208 Based on these findings a phase I clinical trial 
was initiated to test the combination of ruxolitinib and panobi-
nostat in myelofibrosis patients (http://www.clinicaltrials.gov/, 
NCT01433445). As mentioned, the disturbance of the associa-
tion between JAK2V617F and its chaperone HSP90 can lead to 
lower JAK2V617F expression levels. This can also be achieved 
by inhibiting HSP90. It has been shown that the inhibition of 
HSP90 chaperone function by e.g., PU-H71 or AUY922 leads 
to the loss of binding to JAK2 resulting in attenuated expres-
sion of JAK2 (V617F) and inhibition of JAK-STAT signaling. 
The combination of a JAK2 inhibitor and a HSP90 inhibitor 
showed enhanced efficacy in the proliferation of JAK2V617F-
positive cells in comparison to each single compound.209,210 
Furthermore, AUY922 was demonstrated to overcome resistance 
to JAK2 inhibitor treatment in cells expressing JAK2V617F.209,211 
Taken together, inhibition of HSP90 and/or the combination 
with JAK2 inhibitors might be a valuable treatment approach to 
test in MPN patients, especially in those who do not respond 
to JAK2 inhibitory treatment. However, it has to be considered 
that HSP90 has many other client proteins besides JAK2 that 
are prone to degradation upon inhibition of HSP90 as well. This 
might lead to additional side effects compared with a more spe-
cific treatment.
In conclusion, a combination of JAK2 inhibitors with 
other agents that have demonstrated a clinical benefit in MPN 
patients might help to further improve the treatment outcome 
target Aurora kinases in the sub-micromolar concentration range 
in intact cells.194
However, most of the JAK inhibitors demonstrate inhibitory 
activity toward more than one JAK family member (or other 
kinases), which, on the other hand, might be beneficial in the 
setting of inflammatory disorders. In line with this, tofacitinib 
(CP-690550, a pan-JAK inhibitor) has been successfully applied 
in patients with rheumatoid arthritis195 and has recently been 
approved by the FDA (Xeljanz®) for the treatment of patients 
with moderately to severely active rheumatoid arthritis.
The majority of ATP-competitive kinase inhibitors bind the 
kinase domain of their respective targets in the active state (also 
known as type I inhibitors); the clinically approved drugs gefi-
tinib, erlotinib, and sunitinib are prominent examples of this 
inhibitor class.196 Most inhibitors developed against Janus kinases 
are type I inhibitors.197 Since kinase domains in their active con-
formation are highly similar to each other it is especially diffi-
cult to accomplish high selectivity by using type I inhibitors. A 
strategy to gain selectivity would be the targeting of the inac-
tive conformation of a kinase domain. This class of compounds 
(type II inhibitors) also acts ATP-competitively but targets an 
extended ATP-binding site by spreading into the hydrophobic 
deep pocket which is only accessible in the inactive conformation 
of the kinase.196 Recently, NVP-BBT594 (originally designed to 
target Bcr-Abl) was described as first compound to bind JAK2 in 
its inactive conformation.197
Some of the JAK targeting compounds (including some that 
are not tested in clinical trials) are also very valuable tools for 
research: some by their pan-JAK activity and some by their speci-
ficity for individual JAKs. Table 2 shows some of these potent 
inhibitors of Janus kinases that are commercially available.
Combination treatment with JAK2 inhibitors. Combinations 
of different kinase inhibitors have been shown to have beneficial 
effects on growth inhibition of JAK2V617F-expressing cells. The 
combination of an Aurora kinase inhibitor with a JAK2 inhibi-
tor has recently been shown to synergistically reduce the prolif-
eration of JAK2V617F-positive cells.194 Also the use of a JAK2 
inhibitor in combination with the suppression of the PI3K/
Akt/mTOR pathway synergistically reduces the proliferation 
of JAK2V617F-positive cells.198,199 Moreover, a combined appli-
cation of an inhibitor of the dual specificity mitogen-activated 
protein kinase kinase (MEK)—selumetinib (AZD6244)—and 
a JAK2 inhibitor has been demonstrated to act synergistically on 
the proliferation of JAK2V617F-positive cells.200
Table 2. A selection of potent commercially available JAK inhibitors
Compound JAK1 JAK2 JAK3 Tyk2 References
AZ960 - 3 9 - 57
BMS911543 356 1 73 66 218
CeP33779 ~72 1.8 85 ~1440 230
JAK inhibitor 1 (Ji1, 
pyridone 6, CMP6)
15 1 5 1 231
NvP-BSK805 ~32 0.5 ~19 ~11 232
TG101209 - 6 169 - 233
iC50 values in nM obtained in in vitro kinase assays.
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type II inhibitors are more efficient in inhibiting JAK2 (V617F) 
activity and reducing the JAK2V617F allele burden compared 
with a type I compound remains to be elucidated. The occur-
rence of JAK2 mutations in MPN patients conferring resistance 
to JAK2 inhibition has not been described so far. However, the 
acquisition of secondary mutations to evade therapeutic targeting 
is a common mechanism in cancer.212 Nevertheless, several muta-
tions in the JAK2 kinase domain that evade JAK2 inhibition 
have been identified in in vitro studies.211,213-215 These mutations 
may also emerge in patients under prolonged JAK2 inhibitory 
treatment. More specific JAK inhibitors are necessary to investi-
gate the above mentioned issues and will provide more insight in 
understanding the perspective of JAK inhibitors in the treatment 
of MPN.
Furthermore, the disease-driving mechanisms in the three 
MPNs with high JAK2V617F levels have not been fully eluci-
dated. It is not well understood how the various genetic aberra-
tions interact and contribute to the pathogenesis of MPN. Thus, 
the elucidation of underlying molecular mechanisms including 
the interplay between the JAK-STAT signaling pathway (with 
JAK2 as central node), other signaling pathways and epigenetic 
abnormalities remains a major subject of research in the field 
of MPN. Better therapies for MPN patients are sought, which 
provide better treatment of symptoms, can efficiently change the 
course of these disorders and increase the patients’ survival time. 
The development of combination treatment approaches affecting 
key cellular regulators (including JAK2 inhibitors as well as other 
drugs) might contribute to reach this goal.
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in comparison to JAK2 inhibitors as single drug. Thereby, the 
efficacy of the treatment can be enhanced while possibly decreas-
ing the drug dosage resulting in reduced toxicity. In addition, 
combining two compounds with different mechanisms of action 
would decrease the probability of developing resistance to either 
of the drug.
Perspectives
The clinical development of ruxolitinib and other JAK inhibitors 
appears to be a breakthrough in the treatment of myelofibrosis 
patients. These drugs significantly improve the patients’ quality 
of life, which is remarkable progress over conventional treatment 
strategies. In addition to the reduction of symptoms, the recent 
data indicate that ruxolitinib treatment leads to a reduction of 
the JAK2V617F allele load and presents a survival advantage. It 
will be interesting to follow up to what extent the ruxolitinib-
induced relief of symptoms and decrease of JAK2V617F allele 
load in myelofibrosis and PV is due to the inhibition of inflam-
matory cytokine action (since ruxolitinib targets both JAK1 and 
JAK2). This will probably only be recognized when data from 
studies with more JAK2-specific inhibitors (e.g., TG101348 
[SAR302503] or BMS911543) will have reached comparable 
stages in clinical studies. It is conceivable that a JAK2-specific 
inhibitor might actually perform less well in comparison to rux-
olitinib, due to a lack of activity against JAK1. It could also be 
possible, that a specific JAK2 inhibitor might be more adequate 
for the treatment of PV, as almost all PV patients carry a mutant 
of JAK2 (V617F or exon 12 mutations) and the inflammatory 
cytokine levels are much lower in PV patients than in myelo-
fibrosis patients. For PV and JAK2V617F-positive ET patients 
a JAK1-targeting inhibitor might also have more undesired side 
effects.
No JAK2-specific compound has yet been approved for clinical 
application and the development of specific JAK inhibitors also 
for other indications besides MPN is still required. Additionally, 
the generation of a JAK2-specific inhibitor targeting the inactive 
state of the kinase (type II inhibitor)197 is especially interesting. If 
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